Why you should listen
Bill Doyle is the executive chair of Novocure, a company commercializing a new therapeutic modality for solid tumors using low-intensity electric fields. Recently, Novocure received FDA approval for its first indication, recurrent Glioblastoma Multiforme (GBM), the most virulent form of brain cancer; it is now conducting additional clinical trials.
In 2002, Doyle co-founded medical device venture firm WFD Ventures, which provides financing and business-building expertise to medical device companies with the potential to make a major impact on patient care, working with entrepreneurs, doctors and scientists to improve medical outcomes and maximize the potential of their innovations.
A graduate of MIT, Doyle stablished the MIT FIRST Scholarship for FIRST Robotics Competition participants admitted to MIT.
Watch Jay Walker's onstage Q&A with Bill Doyle >>